Possible therapeutic vaccines for canine myasthenia gravis: Implications for the human disease and associated fatigue
- 31 March 2007
- journal article
- research article
- Published by Elsevier BV in Brain, Behavior, and Immunity
- Vol. 21 (3), 323-331
- https://doi.org/10.1016/j.bbi.2006.10.001
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+cells and TGF-βProceedings of the National Academy of Sciences of the United States of America, 2006
- Autoimmunity is triggered by cPR-3(105–201), a protein complementary to human autoantigen proteinase-3Nature Medicine, 2003
- Idiotype–anti-idiotype circuit in non-autoimmune mice after immunization with the epitope and complementary epitope 289–308aa of La/SSB: implications for the maintenance and perpetuation of the anti-La/SSB responseJournal of Autoimmunity, 2003
- A Review of Fatigue in People With HIV InfectionJournal of the Association of Nurses in AIDS Care, 1999
- Mechanisms and management of fatigue in progressive neurological disordersCurrent Opinion in Neurology, 1996
- Acquired Myasthenia GravisJournal of Veterinary Internal Medicine, 1990
- Establishment and Functional Implications of B‐cell ConnectivityImmunological Reviews, 1989
- Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptorNeurology, 1988
- Autoimmunity in spontaneous myasthenia gravis in dogsClinical Immunology and Immunopathology, 1984
- Naturally occurring anti-idiotypic antibodies in myasthenia gravis patientsNature, 1983